Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caplin Point Laboratories reported consolidated revenue from operations of ₹510.2 Crores in Q1 FY26, up 11.2% year-on-year, while total revenue rose 11.7% to ₹533.4 Crores. Profit after tax grew 20.7% YoY to ₹150.8 Crores, with PAT margin expanding to 28.3% from 26.2%. EBITDA jumped 17.9% to ₹200.9 Crores with margin expanding 200 basis points to 37.7%, and Basic EPS rose 23.1% to ₹20.10. The US business surged 36% YoY to ₹108.5 Crores. The Board recommended a final dividend of ₹3 (150%) per share for FY25, taking total FY25 dividend to ₹6 (300%). The company holds ₹1,237 Crores in free cash reserves and ₹2,207 Crores in liquid assets, and remains net cash positive while planning ₹1,000+ Crores in capex over the next 2-3 years. Auditor Brahmayya & Co. issued an unmodified review report.
Strong, broad-based growth across revenue, profitability and margins with a clean audit report signals robust business health for shareholders. The doubled total dividend (300% vs FY24) and net cash-positive status with rising cash reserves provide downside protection and potential for further capital returns.